Suppr超能文献

Child A级肝硬化患者的小肝细胞癌:肝切除术与肝移植术的比较

Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation.

作者信息

Bigourdan Jean-Marc, Jaeck Daniel, Meyer Nicolas, Meyer Carole, Oussoultzoglou Elie, Bachellier Philippe, Weber Jean-Christophe, Audet Maxime, Doffoël Michel, Wolf Philippe

机构信息

Centre de Chirurgie Viscérale et de Transplantation (Hôpital de Hautepierre), Strasbourg, France.

出版信息

Liver Transpl. 2003 May;9(5):513-20. doi: 10.1053/jlts.2003.50070.

Abstract

Hepatic resection (HR) is the treatment of choice for small hepatocellular carcinoma (HCC) in a noncirrhotic liver, whereas liver transplantation (LT) offers better results in patients with impaired hepatic function (Child B and C). However, it is still debated whether HR or LT is the best strategy for patients with Child A cirrhosis. We conducted a retrospective study on 37 consecutive patients with Child A cirrhosis and small HCC, treated between 1991 and 1999. Seventeen of these patients, who underwent LT, were compared with 20 patients who underwent HR, and prognostic factors for survival and tumor recurrence were analyzed. The primary endpoints were the intention-to-treat, 3- and 5-year survival, and 3- and 5-year recurrence-free survival. Three- and 5-year patient survival rate both were significantly (P =.04) higher in the LT group (87% and 71%, respectively) than in the HR group (67 and 36% respectively). Similarly, the 3- and 5- year recurrence-free survival rates were 87% and 80% for the LT group, and 52% and 40% for the HR group (P =.03). Absence of microscopic vascular invasion was the only other prognostic factor correlated with significantly better recurrence-free survival (P =.02). Therefore, we concluded that in patients with Child A cirrhosis and small HCC, liver transplantation resulted in better overall and disease-free survival than HR.

摘要

肝切除术(HR)是治疗非肝硬化肝脏中小肝细胞癌(HCC)的首选方法,而肝移植(LT)对肝功能受损(Child B和C级)的患者疗效更佳。然而,对于Child A级肝硬化患者,HR还是LT是最佳治疗策略仍存在争议。我们对1991年至1999年间连续收治的37例Child A级肝硬化合并小肝癌患者进行了一项回顾性研究。将其中接受LT的17例患者与接受HR的20例患者进行比较,并分析生存和肿瘤复发的预后因素。主要终点为意向性治疗、3年和5年生存率以及3年和5年无复发生存率。LT组的3年和5年患者生存率(分别为87%和71%)均显著高于HR组(分别为67%和36%,P = 0.04)。同样,LT组的3年和5年无复发生存率分别为87%和80%,HR组为52%和40%(P = 0.03)。无微小血管侵犯是唯一与显著更好的无复发生存率相关的其他预后因素(P = 0.02)。因此,我们得出结论,对于Child A级肝硬化合并小肝癌患者,肝移植比肝切除术能带来更好的总体生存率和无病生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验